Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2015

View Archived Issues

Targeting Leishmania PEPCK protects mice from parasite challenge

AstraZeneca starts phase I study of MEDI-7352 in patients with osteoarthritis

Researchers present long-term survival data on AVX-701 cancer vaccine

Complexa completes four phase I studies of CXA-10 and plans phase II program

Arch Biopartners' AB-569 receives FDA orphan drug designation

Juniper Pharmaceuticals discloses new intravaginal ring candidates

DBV initiates phase IIa study of Viaskin Milk for milk-induced eosinophilic esophagitis

Novartis discloses vaccine adjuvants

Pharmascience presents new BTK inhibitor

Phase I data for biosimilar adalimumab, BI-695501

WNT-974, a first-in-class porcupine inhibitor in advanced solid tumors

Otsuka's OPB-111077 tested in subjects with advanced cancer

Nimbus' potent TYK2 inhibitor NDI-031301

Tesaro launches Varubi in the U.S.

Array BioPharma and Pierre Fabre collaborate on two novel oncology products

Promising results of a novel therapeutic approach to polycystic ovary syndrome

Starpharma's targeted DEP shows promise in ovarian cancer model

Protagen and Mikrogen agree on codevelopment program for Lyme disease diagnostic assay

Allergan reports interim data for bimatoprost sustained-release implant

Majority of Perrigo shareholders reject Mylan tender offer

Protalix plans phase III trials of PRX-102 for Fabry disease

FDA first to approve Darzalex for multiple myeloma

Otonomy initiates clinical development of OTO-311 for tinnitus

Masaryk University discloses protein kinase inhibitors

Dana-Farber Cancer Institute reports JAK3 inhibitors

Clovis provides FDA with requested clinical data on rociletinib

FDA accepts BMS's sBLA for nivolumab in RCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...